Decibel Therapeutics is a clinical-stage biotechnology company focused on discovering and developing transformative treatments for hearing and balance disorders. Co. is developing its primary gene therapy product candidate, DB-OTO, to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. In addition, Co. is advancing AAV.103 to restore hearing in individuals with mutations in the gap junction beta-2 gene and AAV.104 to restore hearing in individuals with mutations in the stereocilin gene. Co. is also developing DB-020 for the prevention of cisplatin-induced hearing loss, which it is evaluating in patients in a clinical trial. We show 12 historical shares outstanding datapoints in our DBTX shares outstanding history coverage, used to compute DBTX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing DBTX market cap history over the course of time is important for investors
interested in comparing DBTX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of DBTX versus a peer is one thing; comparing
DBTX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like DBTX can fluctuate over the course of history.
With this page we aim to empower investors researching DBTX by allowing them to research the DBTX market cap history. |
Free DBTX Email Alerts:
Video: The Importance of Market Cap
